That is the definition of the European Working Group on Sarcopenia in Older People, revised in 2019, which put low muscle strength at its center.1 It comes up with GLP-1 medicines because part of the weight they take off is lean tissue.2
Why strength comes first
Sarcopenia raises the risk of falls, fractures, physical disability and death. The first European definition in 2010 added muscle function to older definitions based only on muscle mass; the 2019 revision went further and put strength first, because strength predicts those outcomes better than mass does.1
The consensus also sorts the condition by cause and by duration. It is primary, or age-related, when no other cause is evident, and secondary when something besides ageing is at work. It is acute when it has lasted less than 6 months, usually after an illness or injury, and chronic at 6 months or more, which raises the risk of death.1
How it is diagnosed
The 2019 consensus uses three criteria in order:1
- Low muscle strength: sarcopenia is probable.
- Plus low muscle quantity or quality: the diagnosis is confirmed.
- Plus low physical performance: sarcopenia is severe.
Case-finding can start with a short questionnaire called SARC-F. The group notes that ways to measure muscle quantity are available in many clinical settings but not all, and expects muscle quality to matter more as methods improve.1
The cut-off points
- Grip strength: below 27 kg for men and 16 kg for women.
- Chair stand: more than 15 seconds for five rises from a chair.
- Muscle in the arms and legs, by DXA or a similar method: below 20 kg for men and 15 kg for women, or below 7.0 and 5.5 kg per square meter of height.
- Performance: walking speed of 0.8 meters a second or less, or a short physical performance battery score of 8 or less.
- Other performance tests: 20 seconds or more for the timed up-and-go test, or not completing a 400-meter walk or needing 6 minutes or more.
EWGSOP2, table 3; the values are set for European populations.1
Where GLP-1 weight loss fits
One related condition is set apart. Sarcopenic obesity, reduced lean body mass together with excess fat, is most often reported in older people. The consensus says obesity makes sarcopenia worse, increases fat infiltration into muscle, lowers physical function and raises the risk of death, but treats sarcopenic obesity as a distinct condition whose definition is still being worked out.1
The body scans in the GLP-1 trials measured lean mass, not strength, so they cannot show who met this definition. What they show is how much lean tissue went with the weight. In the Zepbound scan study, lean tissue was about a quarter of the weight lost, and 24% for people aged 65 and over, against 26% for those under 50.2 An MRI study of the thigh in people with diabetes on tirzepatide found muscle volume fell by about as much as expected for the weight lost, while fat inside the muscle fell more than expected.3
The 2025 joint advisory from four medical societies names older age among the situations in which low protein and muscle loss are a greater concern. It recommends resistance training, alone or with aerobic exercise, to help preserve lean mass during weight loss, and notes that aerobic activity alone does less.4 For strength, the consensus uses two tests, grip strength and the chair stand.1
Sources
- Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16-31. doi:10.1093/ageing/afy169
- Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab 2025;27:2720-2729. doi:10.1111/dom.16275
- Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol 2025;13:482-493. doi:10.1016/S2213-8587(25)00027-0
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336
Related analyses
Muscle loss on Zepbound and Wegovy: how much of the weight lost is fat, and how much is muscle
How much protein to eat on Zepbound or Wegovy: the targets, calculated for your weight
What to eat on a GLP-1: the priorities of four medical societies, with a day you can build
Why people stop GLP-1 medications: how many quit, why, and how many come back
Log a simple strength check each month, such as chair rises, next to your weight.
Open Dose Insider